D-dimer tests demand growing in China amid COVID-19, says GlobalData

The significance of monitoring D-dimer levels in COVID-19 cases during treatment is set to drive the demand for D-dimer tests market in China at a compound annual growth rate (CAGR) about 10% between 2020 and 2025, forecasts GlobalData, a leading data and analytics company.

GlobalData’s latest report, ‘Hemostasis Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)’, reveals Siemens Healthineers AG, Quidel Corp and Werfen Life Group SAU were the leading players in China in 2020.

Gundreddy Gopinadh, Medical Devices Analyst at GlobalData, comments: “D-dimer test is often used as a biomarker to diagnose conditions such as pulmonary embolism, deep vein thrombosis and disseminated intravascular coagulation. Physicians are preferring D-dimer tests as potential prognostic marker to assess the disease severity of the COVID-19 patients.

D-dimer tests are beneficial in monitoring and are a useful tool in predicting the patient’s progression of COVID-19 related risks such as thromboembolism and cytokine storm. D-dimer testing can be a helpful tool to decide whether a COVID-19 patient requires hospital admission in the first week of the infection and help in timely medical interventions.

Mr Gopinath concludes: “In China, COVID-19 cases have grown significantly in the past few weeks and there is a growing concern this disease may spread fast and to a much wider geographic region compared to first time it was reported in 2019. In China, D-dimer point of care (POC) tests market accounted for 40% of the D-dimer tests market in 2020. Growing number of severe COVID-19 infected patients and the necessity for quick coagulopathy testing is expected to further boost the D-dimer POC tests market in the country.”

More Media